(Q40745357)

23 September 2017

title

Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease (English)

1 reference

23 September 2017

Arun K Ghosh

1

1 reference

23 September 2017

Elizabeth Pretzer

2

1 reference

23 September 2017

Hanna Cho

3

1 reference

23 September 2017

Khaja Azhar Hussain

4

1 reference

23 September 2017

Nejat Düzgüneş

5

1 reference

23 September 2017

publication date

1 April 2002

1 reference

23 September 2017

1 reference

23 September 2017

volume

54

1 reference

23 September 2017

issue

1

1 reference

23 September 2017

page(s)

29-36

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Antiviral therapy for human immunodeficiency virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P2-LIGANDS FOR HIV-1 PROTEASE INHIBITORS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

CYCLIC SULFONE-3-CARBOXAMIDES AS NOVEL P-LIGANDS FOR Ro 31-8959 BASED HIV-1 PROTEASE INHIBITORS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Chromatographic measurement of drug-protein interaction: determination of HIV protease inhibitor-serum albumin association

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Liposomes modulate human immunodeficiency virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

HTLV-III gag protein is processed in yeast cells by the virus pol-protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

HIV-1 protease inhibitors and the MDR1 multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Human immunodeficiency virus protease inhibitors. From drug design to clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900209-1

7 January 2021

10.1016/S0166-3542(01)00209-1

Identifiers

DOI

1 reference

23 September 2017

1 reference